OnabotulinumtoxinA Injection of Sphenopalatine Ganglion May Not Improve Trigeminal Neuralgia
The injection of onabotulinumtoxinA toward the sphenopalatine ganglion in patients with trigeminal neuralgia may not reduce the number of attacks.
Treatments
Galcanezumab Improves Health-Related Quality of Life and Disability in Patients With Migraine
Galcanezumab, a monoclonal antibody against calcitonin gene-related peptide, may significantly improve daily functioning, disability, and health-related quality of life in a rapid and sustained fashion in patients with migraine.
Systematic Review of Botulinum Toxin as Migraine Prophylactic
Botulinum toxin was found to reduce migraine frequency in adults with chronic migraine by two days per month without significant adverse events.
Direct Oral Anticoagulants Preferable to Warfarin for Secondary Prevention of Stroke in Patients with AF
Treatment with direct oral anticoagulants (DOAC) at discharge following acute ischemic stroke among patients with atrial fibrillation is an effective and safe treatment option, with a superior risk-benefit ratio compared with warfarin.
Perineural Injection of Platelet-Rich Plasma for Peripheral Neuropathy Pain
Perineural injection of platelet-rich plasma may improve pain and numbness associated with diabetic peripheral neuropathy, and enhance peripheral nerve function.
Does Vitamin D Supplementation Reduce ADHD Symptoms?
“We found that vitamin D supplementation may alleviate ADHD symptoms, which were supported by improvements in ADHD total scores, inattention scores, hyperactivity scores, and behavior scores,” the authors stated.
Smartphone-Based Progressive Muscle Relaxation May Reduce Monthly Headache Days in Migraine
The use of a smartphone-based progressive muscle relaxation was found to be associated with a reduction in monthly headache days and depression scores in patients with migraine.
Dalfampridine May Improve Information Processing Speed in Patients With MS
Dalfampridine is an effective treatment option for improving information processing in multiple sclerosis.
Recently Approved Medication for Spinal Muscular Atrophy Costs $2.1 Million for Single Dose
Its extremely high price tag means that a lifesaving medication to treat young children with spinal muscular atrophy is simply too expensive for most families.
Green Tea Extract Shows No Significant Benefit for Multiple System Atrophy
Findings from PROMESA tiral show orally administered epigallocatechin gallate, a component extracted from green tea, treatment produced no significant benefits in modifying disease progression for people with multiple system atrophy.
Next post in Neurodegenerative Diseases
